Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib.
Govindan
R
R
Behnken
D
D
Read
W
W
McLeod
H
H
D000284:Administration, Oral; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors*; D005260:Female; D005500:Follow-Up Studies; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D011013:Pneumonectomy / Q000379:methods; D011182:Postoperative Care; D011799:Quinazolines / Q000008:administration & dosage*; D018570:Risk Assessment; D012494:Sampling Studies; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
D011799:Quinazolines; D004815:Epidermal Growth Factor; D000077156:Gefitinib